| Bristol-Myers Squibb SA - Lenalidomid BMS 20 mg, Hartkapseln | | 68490 | | 06 | | Lenalidomid BMS 20 mg | | Hartkapseln | | L04AX04 | | Lenalidomide | | 14.06.2021 | | |
| | Composition | | lenalidomidum 20 mg, lactosum 244.5 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.8 mg, magnesii stearas, Kapselhülle: gelatina, E 171, E 132, E 172 (flavum), Drucktinte: lacca, propylenglycolum, E 172 (nigrum), kalii hydroxidum, pro capsula. | | Packungsbestandteile | | Capsules | | | | | Principe actif | Concentr. |
|---|
| Lenalidomidum | 20 mg |
| | BAG: Principe actif | Concentr. |
|---|
| Lenalidomidum | 20 mg |
| | | | Agents auxilliaires | Concentr. | informations additionels |
|---|
| (Flavum) | | | | (Nigrum) | | | | Carmellosum Natricum Conexum | | | | Cellulosum Microcristallinum | | | | E 132 | | color. | | E 171 | | color. | | E 172 | | color. | | Gelatina | | Kapselhülle | | Kalii Hydroxidum | | | | Lacca | | Drucktinte | | Lactosum | 244.5 mg | | | Magnesii Stearas | | | | Pro Capsula | | | | Propylenglycol | | |
| |
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 006 | 21 | 821.96 | 910.35 | A | LS | Oui |
|
|
